Aptose Biosciences Inc. 8-K

What Happened

• Aptose Biosciences Inc. (APTOF) filed a Form 8-K on March 31, 2026 to provide Regulation FD disclosure: the company issued a press release on that date, which is attached as Exhibit 99.1 to the filing.
• The filing states the press release is furnished under General Instruction B.2 of Form 8-K and therefore “shall not be deemed to be ‘filed’” for purposes of Section 18 of the Securities Exchange Act.

Key Details

• Filing date: March 31, 2026 (Form 8-K).
• Item reported: Item 7.01 (Regulation FD disclosure); exhibit listed under Item 9.01(d).
• Exhibit: 99.1 — Press Release dated March 31, 2026.
• EDGAR note: Information in the press release is furnished, not filed, and is not automatically incorporated by reference into other SEC filings.

Why It Matters

• The 8-K tells investors that Aptose publicly released information on March 31, 2026; investors should read the attached press release (Exhibit 99.1) for the full content and any material announcements.
• Because the press release is furnished rather than filed, the company disclaims the Section 18 liability protection that applies to filed materials; this is a procedural disclosure about how the information is reported to the SEC, not a statement about the substance (e.g., earnings, executive changes, merger activity).
• If you follow Aptose for news on earnings, clinical updates, or management changes, check the press release text directly and monitor subsequent SEC filings for any items that are formally filed (e.g., earnings 8-Ks under Item 2.02 or officer changes under Item 5.02).